^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    EP-201

    i
    Other names: EP-201, EP 201, AST-201, IGFBP2 Vaccine
    Associations

    News

    Trials
    Company:
    Aston Sci., EpiThany, University of Washington
    Drug class:
    IGF binding protein 2 stimulant
    Associations

    News

    Trials
    over2years
    Cornerstone4: Adjuvant Therapeutic Cancer Vaccine (AST-201, pUMVC3-hIGFBP-2) in Patients With Advanced Ovarian Cancer (clinicaltrials.gov)
    P2, N=98, Not yet recruiting, Aston Sci. Inc. | Trial completion date: Aug 2027 --> Nov 2027 | Initiation date: Aug 2023 --> Nov 2023
    Trial completion date • Trial initiation date
    |
    IFNG (Interferon, gamma)
    |
    carboplatin • paclitaxel • EP-201 • Leukine (sargramostim)
    almost3years
    Cornerstone4: Adjuvant Therapeutic Cancer Vaccine (AST-201, pUMVC3-hIGFBP-2) in Patients With Advanced Ovarian Cancer (clinicaltrials.gov)
    P2, N=98, Not yet recruiting, Aston Sci. Inc.
    New P2 trial • Metastases
    |
    IFNG (Interferon, gamma)
    |
    carboplatin • paclitaxel • EP-201 • Leukine (sargramostim)
    over8years
    IGFBP-2 Vaccine and Combination Chemotherapy in Treating Patients With Stage III-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Undergoing Surgery (clinicaltrials.gov)
    P2; N=38; Recruiting; Sponsor: University of Washington; N=56 --> 38; Trial primary completion date: Dec 2017 --> Jun 2018
    Trial primary completion date • Enrollment change • Clinical
    |
    CD4 (CD4 Molecule) • CD27 (CD27 Molecule) • IGFBP2 (Insulin-like growth factor binding protein 2)
    |
    carboplatin • paclitaxel • EP-201